Document Detail

Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.
MedLine Citation:
PMID:  21158486     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To examine resource utilization and healthcare costs associated with the use of exenatide versus glargine in type 2 diabetes (T2D) patients.
METHODS: A retrospective analysis comprised of patients with T2D initiating exenatide (n = 7,255) or glargine (n = 2,819) between 04/01/2005 and 06/30/2007. Propensity score matching was used (2,506 matched pairs) to control for baseline demographic, clinical, resource use, and cost variables to balance treatment groups. Mean medical costs and other cost components were estimated using nonparametric bootstrapping.
RESULTS: Exenatide-treated patients had 19% lower likelihood of all-cause hospitalizations (odds ratio [OR]: 0.81, p = 0.009) compared to glargine-treated patients. Exenatide-treated patients had significantly lower total medical costs of $2,597 (p = 0.008). Exenatide-treated patients had significantly lower inpatient costs of $1,968 (p = 0.004) and outpatient costs of $1,324 (p = 0.011), but higher prescription costs of $706 (p < 0.001). Exenatide-treated patients further incurred lower hospitalization costs of $1,910 (p = 0.005) and physician office visit costs of $608 (p = 0.008).
KEY LIMITATIONS: Lack of availability of clinical measures including duration of diabetes, severity of T2D and lack of control for unmeasured confounding.
CONCLUSIONS: Patients initiating exenatide treatment had significantly lower healthcare resource utilization and total medical costs. Cost offsets were observed in inpatient and outpatient costs despite higher prescription costs.
Manjiri Pawaskar; Anthony Zagar; Tomoko Sugihara; Lizheng Shi
Related Documents :
21459736 - Impact of complete blood count sampling time change on white blood cell andabsolute neu...
21358686 - The clinical features and outcome of 2009 h1n1 influenza infection in allo-sct patients...
8893926 - Unplanned returns to the accident and emergency department--why do they come back?
19413166 - Measuring the opportunity loss of time spent boarding admitted patients in the emergenc...
7490196 - An audit of the clinical management of urinary tract infection in childhood.
16672676 - Clinical decision-making in blood pressure management of patients with diabetes mellitu...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-12-15
Journal Detail:
Title:  Journal of medical economics     Volume:  14     ISSN:  1941-837X     ISO Abbreviation:  J Med Econ     Publication Date:  2011  
Date Detail:
Created Date:  2011-01-18     Completed Date:  2011-06-08     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  9892255     Medline TA:  J Med Econ     Country:  England    
Other Details:
Languages:  eng     Pagination:  16-27     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Costs and Cost Analysis
Databases, Factual
Diabetes Mellitus, Type 2 / drug therapy*,  economics*
Health Services / utilization*
Hypoglycemic Agents / economics,  therapeutic use*
Insulin / analogs & derivatives*,  economics,  therapeutic use
Insulin, Long-Acting
Middle Aged
Peptides / economics,  therapeutic use*
Retrospective Studies
Venoms / economics,  therapeutic use*
Young Adult
Reg. No./Substance:
0/Hypoglycemic Agents; 0/Insulin; 0/Insulin, Long-Acting; 0/Peptides; 0/Venoms; 0/glargine; 9P1872D4OL/exenatide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Secreted proteins from adipose tissue and skeletal muscle - adipokines, myokines and adipose/muscle ...
Next Document:  Localised drug release using MRI-controlled focused ultrasound hyperthermia.